Dynavax Technologies | DVAX - Stock


Dynavax Technologies reported $73.29M in Stock for its fiscal quarter ending in September of 2025.



Stock Change Date
AbbVie USD 4.95B 13M Dec/2025
Adma Biologics USD 206.46M 9.8M Dec/2025
Amgen USD 6.22B 121M Dec/2025
AstraZeneca USD 6.59B 126M Sep/2025
Biogen USD 2.17B 41.3M Dec/2025
BioMarin Pharmaceutical USD 1.3B 83.29M Dec/2025
Bristol-Myers Squibb USD 2.76B 21M Sep/2025
Gilead Sciences USD 1.78B 40M Sep/2025
Glaxosmithkline GBP 6.12B 46M Sep/2025
Merck USD 6.44B 157M Sep/2025
Nektar Therapeutics USD 14.46M 1.78M Jun/2024
Neurocrine Biosciences USD 69M 300K Dec/2025
Novartis USD 6.42B 114M Sep/2025
Pfizer USD 11.47B 201M Sep/2025
Regeneron Pharmaceuticals USD 3.2B 53.6M Dec/2025
Roche Holding CHF 7.6B 9M Jun/2025
Sarepta Therapeutics USD 914.74M 162.42M Dec/2025
TG Therapeutics USD 125.59M 21.37M Dec/2025
Vertex Pharmaceuticals USD 1.69B 60M Dec/2025